Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

New England Journal of Medicine

Volumn 347, Issue 13, 2002, Pages 975-982

  Fried, Michael W ^a   Shiffman, Mitchell L ^b   Rajender Reddy, K ^c   Smith, Coleman ^d   Marinos, George ^e   Gonçales Jr , Fernando L ^f   Häussinger, Dieter ^g   Diago, Moises ^h   Carosi, Giampiero ⁱ   Dhumeaux, Daniel ^j   Craxi, Antonio ^k   Lin, Amy ^l   Hoffman, Joseph ^l   Yu, Jian ^l  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d St Paul MI   (United States)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f Cidade Universitária Zeferino Vaz   (Brazil)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h Hospital General Universitario   (Spain)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j HENRI MONDOR HOSPITAL   (France)

^k UNIVERSITY OF PALERMO   (Italy)

^l HOFFMANN LA ROCHE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; REBETRON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HEPATITIS VIRUSES; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL;

EID: 0037179698     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa020047     Document Type: Article

References (22)

1. Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999;31:Suppl 1:152-9.
2. EASL International Consensus Conference on hepatitis C: Paris, 26-28, February 1999: consensus statement. J Hepatol 1999;30:956-61.
3. Booth JC, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001;49:Suppl 1:I-1-I-21.
4. Canadian Association for the Study of the Liver. Canadian consensus conference on the management of viral hepatitis. Can J Gastroenterol 2000;14:Suppl B:5B-20B.
5. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-12.
6. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
7. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
8. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433-8.
9. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
10. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-80.
11. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
12. Pockros PJ, Carithers R, Desmond P, et al. Evaluation of two doses of peginterferon alfa-2a for the treatment of chronic hepatitis C (CHC). In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16-19, 2001. Washington, D.C.: American Society for Microbiology, 2002:285. abstract.
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
14. Xu Z-X, Hoffman J, Patel I, Joubert P. Single-dose safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon a-2a (IFN α-2a) to healthy subjects. Hepatology 1998;28: Suppl:702A. abstract.
15. Nieforth KA, Nadeau R, Patel IH, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther 1996;59:636-46.
16. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990;19:390-9.
17. Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 1999;30:Suppl:190A. abstract.
18. Germer JJ, Rys PN, Thorvilson JN, Persing DH. Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol 1999;37:2625-30.
19. Marcus R, Peritz E, Gabriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976;63:655-60.
20. Bauer P. Multiple testing in clinical trials. Stat Med 1991;10:871-90.
21. Breslow NE, Day NE. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. Lyons, France: International Agency for Research on Cancer, 1980. (IARC scientific publications no. 32.)
22. Ferenci P, Shiffman ML, Fried MW, et al. Early prediction of response to 40 kDa peginterferon alfa-2a (Pegasys) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). Hepatology 2001;34:351A. abstract.